Collagen gel droplet-embedded culture-drug sensitivity test and Ki67 expression in estrogen receptor-positive and HER2-negative breast cancer

Tozuka,Katsunori; Horiguchi,Jun; Takata,Daisuke; Rokutanda,Nana; Nagaoka,Rin; Tokiniwa,Hideaki; Kikuchi,Mami; Satou,Ayako; Takei,Hiroyuki; Takeyoshi,Izumi

doi:10.3892/mco.2012.4

Collagen gel droplet-embedded culture-drug sensitivity test and Ki67 expression in estrogen receptor-positive and HER2-negative breast cancer

Authors:
- Katsunori Tozuka
- Jun Horiguchi
- Daisuke Takata
- Nana Rokutanda
- Rin Nagaoka
- Hideaki Tokiniwa
- Mami Kikuchi
- Ayako Satou
- Hiroyuki Takei
- Izumi Takeyoshi
View Affiliations

Affiliations: Department of Thoracic and Visceral Organ Surgery, Gunma University Graduate School of Medicine, Maebashi, Gunma 371-8511, Japan, Division of Breast Surgery, Saitama Cancer Center, Kitaadachi, Saitama 362-0806, Japan
Published online on: July 26, 2012 https://doi.org/10.3892/mco.2012.4
Pages: 93-99

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Anthracyclines and taxanes are standard anticancer drugs used in breast cancer chemotherapy. In general, the efficacy of chemotherapy is lower in patients with estrogen receptor (ER)-positive tumors compared to patients with ER-negative tumors. Although less chemosensitive, ER-positive disease includes a subset of patients who significantly benefit from adjuvant chemotherapy. The collagen gel droplet-embedded culture-drug sensitivity test (CD-DST) is an in vitro chemosensitivity test that has several advantages over conventional tests. The aim of the present study was to examine the correlation between CD-DST and the expression of Ki67, an indicator of tumor proliferation, to evaluate the efficacy of anthracyclines and taxanes in patients with ER-positive and human epidermal growth factor receptor 2 (HER2)-negative breast cancer. CD-DST was performed in 68 patients with ER-positive and HER2-negative breast cancer between August 2001 and November 2006. The specimens obtained during surgery were used for the CD-DST and immunohistological examination of Ki67 expression. Chemosensitivity to the anticancer drugs adriamycin (ADM), epirubicin (EPI), docetaxel (DOC) and paclitaxel (PTX) was estimated using CD-DST. Results obtained from the CD-DST showed the chemosensitivity to each anticancer drug to be ADM, 20.4%; EPI, 67.3%; DOC, 66.7% and PTX, 43.6%. Ki67 expression was significantly higher in the group that was sensitive to DOC compared to the group that was resistant to DOC (P=0.021) and PTX (P=0.033). In addition, a significant correlation was observed between a Ki67 labeling index (LI) of >30% and chemosensitivity to PTX. In conclusion, results obtained from CD-DST and Ki67 expression levels are able to identify a subset of patients with ER-positive and HER2-negative breast cancer who exhibit sensitivity to chemotherapy, particularly to taxane therapy.

View Figures

View References

1.	Early Breast Cancer Trialists’ Collaborative Group (EBCTCG): Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomized trials. Lancet. 365:1687–1717. 2005.
2.	Martin M, Pienkowski T, Mackey J, et al: Breast Cancer International Research Group 001 Investigators: Adjuvant docetaxel for node-positive breast cancer. N Engl J Med. 352:2302–2313. 2005.
3.	Martin M, Segui MA, Anton A, et al: Breast Cancer International Research Group 001 Investigators: Adjuvant docetaxel for node-positive breast cancer. N Engl J Med. 363:2200–2210. 2010.
4.	Sparano JA, Wang M, Martino S, et al: Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med. 358:1663–1671. 2008.
5.	Conforti R, Boulet T, Tomasic G, et al: Breast cancer molecular subclassification and estrogen receptor expression to predict efficacy of adjuvant anthracyclines-based chemotherapy: a biomarker study from two randomized trials. Ann Oncol. 18:1477–1483. 2007.
6.	Berry DA, Cirrincione C, Henderson IC, et al: Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA. 295:1658–1667. 2006.
7.	Regan MM, Viale G, Mastropasqua MG, et al: Re-evaluating adjuvant breast cancer trials: assessing hormone receptor status by immunohistochemical versus extraction assays. J Natl Cancer Inst. 98:1571–1581. 2006.
8.	Bear HD, Anderson S, Brown A, et al: The effect on tumor response adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from national surgical adjuvant breast and bowel project protocol B-27. J Clin Oncol. 21:4165–4174. 2003.
9.	Stearns V, Singh B, Tsangaris T, et al: A prospective randomized pilot study to evaluate predictors of response in serial core biopsies to single agent neoadjuvant doxorubicin or paclitaxel for patients with locally advanced breast cancer. Clin Cancer Res. 9:124–133. 2003.
10.	Kuerer HM, Newman LA, Smith TL, et al: Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol. 17:460–469. 1999.
11.	Paik S, Tang G, Shak S, et al: Gene expression and benefit of chemotherapy in women with node negative, estrogen receptor-positive breast cancer. J Clin Oncol. 24:3726–3734. 2006.
12.	Hayes DF, Thor AD, Dressler LG, et al; Cancer and Leukemia Group B (CALGB) Investigators: HER2 and response to paclitaxel in node-positive breast cancer. N Engl J Med. 357:1496–1506. 2007.
13.	Hugh J, Hanson J, Cheang MCU, et al: Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial. J Clin Oncol. 27:1168–1176. 2009.
14.	Penault-Llorca F, Andre F, Sagan C, et al: Ki67 expression and docetaxel efficacy in patients with estrogen receptor-positive breast cancer. J Clin Oncol. 27:2809–2815. 2009.
15.	Litman T, Druley TE, Stein WD, et al: From MDR to MXR: new understanding of multidrug resistance systems, their properties and clinical significance. Cell Mol Life Sci. 58:931–959. 2001.
16.	Yamamoto N, Tamura T, Murakami H, et al: Randomized pharmacokinetic and pharmacodynamic study of docetaxel: dosing based on body-surface area compared with individualized dosing based on cytochrome P450 activity estimated using a urinary metabolite of exogenous cortisol. J Clin Oncol. 23:1061–1069. 2005.
17.	Miyoshi Y, Taguchi T, Kim SJ, et al: Prediction of response to docetaxel by immunohistochemical analysis of CYP3A4 expression in human breast cancers. Breast Cancer. 12:11–15. 2005.
18.	Hasegawa S, Miyoshi Y, Egawa C, et al: Mutational analysis of the class I beta-tubulin gene in human breast cancer. Int J Cancer. 101:46–51. 2002.
19.	Burkhart CA, Kavallaris M and Band Horwitz S: The role of beta-tubulin isotype in resistance to antimitotic drugs. Biochim Biophys Acta. 1471:1–9. 2001.
20.	Coon JS, Marcus E, Gupta-Burt S, et al: Amplification and overexpression of topoisomerase IIα predict response to anthracycline-based therapy in locally advanced breast cancer. Clin Cancer Res. 8:1061–1067. 2002.
21.	Anand S, Penrhyn-Lowe S and Venkitaraman AR: AURORA-A amplification overrides the mitotic spindle assembly checkpoint, inducing resistance to taxol. Cancer Cell. 3:51–62. 2003.
22.	Sjostrom J, Blomqvist C, Heikkila P, et al: Predictive value of p53, mdm-2, p21, and mib-1 for chemotherapy response in advanced breast cancer. Clin Cancer Res. 6:3103–3110. 2000.
23.	Sjostrom J, Blomqvist C, von Boguslawski K, et al: The predictive value of bcl-2, bax, bcl-xL, bag-1, fas, and fasL for chemotherapy response in advanced breast cancer. Clin Cancer Res. 8:811–816. 2002.
24.	Yokomizo A, Ono M, Nanri H, et al: Cellular levels of thioredoxin associated with drug sensitivity to cisplatin, mitomycin C, doxorubicin, and etoposide. Cancer Res. 55:4293–4296. 1995.
25.	Sahin AA, Ro J, Ro JY, et al: Ki67 immunostaining in node negative stage I/II breast carcinoma. Significant correlation with prognosis. Cancer. 68:549–557. 1991.
26.	Domagala W, Markiewski M, Harezga B, et al: Prognostic significance of tumor cell proliferation rate as determined by the MIB-1 antibody in breast carcinoma: its relationship with vimentin and p53 protein. Clin Cancer Res. 2:147–154. 1996.
27.	Trihia H, Murray S, Price K, et al: Ki67 expression in breast carcinoma. Its association with grading systems, clinical parameters, and other prognostic factors - a surrogate marker? Cancer. 97:1321–1331. 2003.
28.	Chang J, Ormerod M, Powles TJ, et al: Apoptosis and proliferation as predictors of chemotherapy response in patients with breast carcinoma. Cancer. 89:2145–2152. 2000.
29.	Archer CD, Parton M, Smith IE, et al: Early changes in apoptosis and proliferation following primary chemotherapy for breast cancer. Br J Cancer. 89:1035–1041. 2003.
30.	Goldhhirsch A, Ingle JN, Gelber RD, et al: Thresholds for therapies: highlights of the St Gallen international expert consensus on primary therapy early breast cancer. Ann Oncol. 20:1319–1329. 2009.
31.	Kobayashi H: Development of a new in vitro chemosensitivity test using collagen gel droplet embedded culture and image analysis for clinical usefulness. Recent Results Cancer Res. 161:48–61. 2003.
32.	Yasuda H, Takada T, Wada K, et al: A new in-vitro drug sensitivity test (collagen-gel droplet embedded-culture drug sensitivity test) in carcinomas of pancreas and biliary tract: possible clinical utility. J Hepatobiliary Pancreat Surg. 5:261–268. 1998.
33.	Higashiyama M, Kodama K, Yokouchi H, et al: Immunohistochemical p53 protein status in nonsmall cell lung cancer is a promising indicator in determining in vitro chemosensitivity to some anticancer drugs. J Surg Oncol. 68:19–24. 1998.
34.	Takamura Y, Kobayashi H, Taguchi T, et al: Prediction of chemotherapeutic response by collagen gel droplet embedded culture-drug sensitivity test in human breast cancers. Int J Cancer. 98:450–455. 2002.
35.	Von Hoff DD: He’s not going to talk about in vitro predictive assay again, is he? J Natl Cancer Inst. 82:96–101. 1990.
36.	Kern DH, Drogemuller CR, Kennedy MC, et al: Development of miniaturized, improved nucleic acid precursor incorporation assay for chemosensitivity testing of human solid tumors. Cancer Res. 45:5436–5441. 1985.
37.	Fruehauf JP and Bosanquet AG: In vitro determination of drug response: a discussion of clinical applications. Principles Prac Oncol Updates. 7:121993.
38.	Carmichael J, De Graff WG, Gazdar AF, et al: Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. Cancer Res. 47:936–942. 1987.
39.	Wilbur DW, Camacho ES, Hilliard DA, et al: Chemotherapy of non-small cell lung carcinoma guided by an in vitro drug resistance assay measuring total tumour cell kill. Br J Cancer. 65:27–32. 1992.
40.	Mechetner E, Kyshtoobayeva A, Zonis S, et al: Levels of multidrug resistance (MDR1) P-glycoprotein expression by human breast cancer correlate with in vitro resistance to taxol and doxorubicin. Clin Cancer Res. 4:389–398. 1998.
41.	Furukawa T, Kubota T and Hoffman RM: Clinical application of the histoculture drug response assay. Clin Cancer Res. 1:305–311. 1995.
42.	Yamamoto Y, Watanabe Y, Ishida N, et al: Collagen gel droplet-embedded culture drug sensitivity test in human breast cancer. Gan To Kagaku Ryoho. 35:793–796. 2008.(In Japanese).
43.	Paik S, Bryant J, Park C, et al: erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer. J Natl Cancer Inst. 90:1361–1370. 1998.
44.	Henderson IC, Berry DA, Demetri GD, et al: Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol. 21:976–983. 2003.
45.	Tham YL, Gomez LF, Mohsin S, et al: Clinical response to neoadjuvant docetaxel predicts improved outcome in patients with large locally advanced breast cancers. Breast Cancer Res Treat. 94:279–284. 2005.
46.	Learn PA, Yeh IT, McNutt M, et al: HER-2/neu expression as a predictor of response to neoadjuvant docetaxel in patients with operable breast carcinoma. Cancer. 103:2252–2260. 2005.
47.	de Azambuja E, Cardoso F, de Castro G Jr, et al: Ki67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12,155 patients. Br J Cancer. 96:1504–1513. 2007.
48.	Cheang MC, Chia SK, Voduc D, et al: Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst. 101:736–750. 2009.
49.	Stuart-Harris R, Caldas C, Pinder SE and Pharoah P: Proliferation markers and survival in early breast cancer: a systematic review and meta-analysis of 85 studies in 32,825 patients. Breast. 17:323–334. 2008.
50.	Urruticoechea A, Smith IE and Dowsett M: Proliferation marker Ki-67 in early breast cancer. J Clin Oncol. 23:7212–7220. 2005.
51.	Paik S, Shak S, Tang G, et al: A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 351:2817–2826. 2004.
52.	van de Vijver MJ, He YD, van’t Veer LJ, et al: A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med. 347:1999–2009. 2002.
53.	Sparano JA and Paik S: Development of the 21-gene assay and its application in clinical practice and clinical trials. J Clin Oncol. 26:721–728. 2008.
54.	Cardoso F, van’t Veer L, Rutgers E, et al: Clinical application of the 70-gene profile: the MINDACT trial. J Clin Oncol. 26:729–735. 2008.